462 related articles for article (PubMed ID: 17387335)
21. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
22. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
23. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
24. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
Ramezani A; Hawley RG
Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
[TBL] [Abstract][Full Text] [Related]
25. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
Liu CL; Ye P; Yen BC; Miao CH
Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
[TBL] [Abstract][Full Text] [Related]
26. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
Xu L; Mei M; Ma X; Ponder KP
J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
[TBL] [Abstract][Full Text] [Related]
27. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
[TBL] [Abstract][Full Text] [Related]
28. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
29. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
30. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
[TBL] [Abstract][Full Text] [Related]
31. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
32. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
[TBL] [Abstract][Full Text] [Related]
33. Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.
Ramezani A; Zweier-Renn LA; Hawley RG
Thromb Haemost; 2011 Apr; 105(4):676-87. PubMed ID: 21264447
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.
Miao CH; Ye P; Thompson AR; Rawlings DJ; Ochs HD
Blood; 2006 Jul; 108(1):19-27. PubMed ID: 16507778
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic stem cell therapy.
Wang JJ; Kuang Y; Zhang LL; Shen CL; Wang L; Lu SY; Lu XB; Fei J; Gu MM; Wang ZG
Genet Mol Res; 2013 May; 12(2):1511-21. PubMed ID: 23765957
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
37. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.
Doering CB
Methods Mol Biol; 2008; 433():203-12. PubMed ID: 18679625
[TBL] [Abstract][Full Text] [Related]
38. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
39. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
[TBL] [Abstract][Full Text] [Related]
40. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]